Avantor Inc.
AVTR
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
17.1% upsideUndervalued by 17.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.32 Billion |
|---|---|
| Enterprise Value | $9.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.78 |
| Beta | 0.94 |
| Outstanding Shares | 676,200,000 |
Return
| Return on Equity | -10.27% |
|---|---|
| Return on Assets | -4.98% |
| Return on Invested Capital | -2.58% |
Valuation & Multiples
| P/E Ratio | -16.43 |
|---|---|
| PEG | 39.96 |
| Price to Sales | - |
| Price to Book Ratio | 1.71 |
| Enterprise Value to Revenue | 1016.9 |
| Enterprise Value to EBIT | -34.33 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 1909.78% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.62%▼ 93.00% |
|---|---|
| Total Invested | $444.31M▼ 91.62% |
| Investors Holding | 129▼ 314.00% |
ESG Score
No data
About Avantor Inc.
12,400 employees
CEO: Michael Stubblefield Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries.
Relevant Senate Committees
Control over taxation and trade policy directly impacts Avantor's profitability, capital investment decisions, and global operations. Medicare pricing policies also affect its healthcare customers.
This committee directly allocates federal discretionary spending, which determines the funding for scientific research, healthcare programs, and government labs—all major customers for Avantor.
Direct oversight of the FDA and NIH, along with influence on education policy, profoundly impacts Avantor's biopharma, healthcare, and education & government customer segments.
The committee's broad jurisdiction over 'Science' and 'Advanced Technologies' directly aligns with Avantor's core business of analytical laboratory instrument manufacturing and its customer base.